{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:48:15Z","timestamp":1777265295667,"version":"3.51.4"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Imatinib mesylate (IM) has changed the management of gastrointestinal stromal tumors (GISTs), especially for adjuvant therapy after radical resection. However, the optimal duration of the adjuvant therapy remains controversial. Therefore, this study evaluated the effect of adjuvant IM duration and plasma drug concentrations on survival outcomes of patients at high risk with GISTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed patients diagnosed with high-risk GIST who underwent radical surgery at the First Affiliated Hospital of Chongqing Medical University between January 2008 and December 2021. Survival outcomes were compared according to adjuvant IM duration (\u22643 years vs. &amp;gt;3 years). Plasma trough concentrations (Cmin) of IM were measured in a subset of patients and analyzed in relation to prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 75 patients (42 males and 33 females), with a median age of 53 (24\u201379) years. Tumors were most commonly located in the small intestine (44 patients, 58.7%) and stomach (23 patients, 30.7%). Kaplan-Meier curve analysis showed that the 5-year relapse-free survival (RFS) rates were 84% and 74% in the groups with treatment duration &amp;gt;3 years and \u22643 years, respectively (P &amp;lt; 0.05), whereas no significant difference in 5-year overall survival (OS) was observed between the two groups (P &amp;gt; 0.05). In the multivariate analysis, treatment duration was not significantly associated with survival benefit (HR\u00a0=\u00a00.53, 95% CI 0.15\u20131.83, P\u00a0=\u00a00.313).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on this retrospective study, adjuvant IM for more than 3 years did not independently improve prognosis in patients with high-risk GIST following radical resection. Moreover, the clinical significance of IM Cmin remains unclear. Therefore, extending adjuvant therapy beyond 3 years is not routinely recommended at present. These findings require further validation through prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1756927","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:27:58Z","timestamp":1777264078000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of adjuvant imatinib treatment for patients with high-risk gastrointestinal stromal tumor"],"prefix":"10.3389","volume":"16","author":[{"given":"Jie","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghui","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongming","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Ao","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingye","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","article-title":"Gastrointestinal stromal tumors: pathology and prognosis at different sites","volume":"23","author":"Miettinen","year":"2006","journal-title":"Semin Diagn Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.2009.108","article-title":"An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system","volume":"144","author":"Woodall","year":"2009","journal-title":"Arch Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-230","article-title":"Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study","volume":"7","author":"Mucciarini","year":"2007","journal-title":"BMC Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20862","article-title":"Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden","volume":"103","author":"Nilsson","year":"2005","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60106-3","article-title":"Gastrointestinal stromal tumor","volume":"382","author":"Joensuu","year":"2013","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70299-6","article-title":"Risk of recurrence of gastrointestinal stromal tumor after surgery: an analysis of pooled population-based cohorts","volume":"13","author":"Joensuu","year":"2012","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70222-9","article-title":"Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumors after 3 years of treatment: an open-label multicenter randomized phase 3 trial","volume":"11","author":"Le Cesne","year":"2010","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60500-6","article-title":"Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumor: a randomized, double-blind, placebo-controlled trial","volume":"373","author":"Dematteo","year":"2009","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00280-012-1970-3","article-title":"Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation","volume":"71","author":"Kang","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2091","article-title":"Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: an analysis of a randomized clinical trial after 10-year follow-up","volume":"6","author":"Joensuu","year":"2020","journal-title":"JAMA Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000493195","article-title":"Relative factors analysis of imatinib trough concentration in Chinese patients with gastrointestinal stromal tumor","volume":"63","author":"Wu","year":"2018","journal-title":"Chemotherapy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.trecan.2017.11.006","article-title":"Gastrointestinal stromal tumors: the GIST of precision medicine","volume":"4","author":"Mei","year":"2018","journal-title":"Trends Cancer"},{"key":"B14","article-title":"Progress in clinical test methods on the protective function of the gastric mucosa; evaluation of mucosal epithelium blood flow by reflectance spectrophotometry","volume":"46","author":"Sato","year":"1988","journal-title":"Nihon Rinsho"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246958","article-title":"Nationwide incidence of sarcomas and connective tissue tumors of intermediate Malignancy over four years using an expert pathology review network","volume":"16","author":"de Pinieux","year":"2021","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.347","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial","volume":"307","author":"Joensuu","year":"2012","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2343","article-title":"A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse","volume":"35","author":"Blay","year":"2024","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.004","article-title":"Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)\u2729","volume":"32","author":"Casali","year":"2021","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.569843","article-title":"Factors influencing the steady-state plasma concentration of imatinib mesylate in patients with gastrointestinal stromal tumors and chronic myeloid leukemia","volume":"11","author":"Chen","year":"2020","journal-title":"Front Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2023.1115141","article-title":"Changes in imatinib plasma trough level during long-term treatment in patients with intermediate- or high-risk gastrointestinal stromal tumors: relationship between covariates and imatinib plasma trough level","volume":"10","author":"Wu","year":"2023","journal-title":"Front Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.12.029","article-title":"Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumors in a real-life setting","volume":"57","author":"Bouchet","year":"2016","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1756927\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:27:59Z","timestamp":1777264079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1756927\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1756927"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1756927","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"1756927"}}